Tas-102
Kidney Carcinoma
National Cancer Institute (NCI)unclassifiedPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
27 Active assets in the Kidney Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
su011248 National Cancer Institute (NCI) | Phase 2 | B |
Crizotinib National Cancer Institute (NCI) | Phase 2 | CCC |
Larotrectinib National Cancer Institute (NCI) | Phase 2 | CCC |
Osimertinib National Cancer Institute (NCI) | Phase 2 | CCC |
Trastuzumab Emtansine National Cancer Institute (NCI) | Phase 2 | CCC |
View all 27 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →